[HTML][HTML] Pre-clinical assessment of chimeric antigen receptor t cell therapy targeting CD19+ B cell malignancy
SI Hu, MC Ko, YH Dai, HA Lin, LC Chen… - Annals of …, 2020 - ncbi.nlm.nih.gov
Background Autologous chimeric antigen receptor (CAR) T cell therapy is a promising
therapeutic strategy for treating hematologic malignancies. A spectrum of serious …
therapeutic strategy for treating hematologic malignancies. A spectrum of serious …
[HTML][HTML] Pre-clinical assessment of chimeric antigen receptor t cell therapy targeting CD19+ B cell malignancy
SI Hu, MC Ko, YH Dai, HA Lin, LC Chen… - Annals of …, 2020 - atm.amegroups.org
Background: Autologous chimeric antigen receptor (CAR) T cell therapy is a promising
therapeutic strategy for treating hematologic malignancies. A spectrum of serious …
therapeutic strategy for treating hematologic malignancies. A spectrum of serious …
[PDF][PDF] Pre-clinical assessment of chimeric antigen receptor t cell therapy targeting CD19+ B cell malignancy
SI Hu, MC Ko, YH Dai, HA Lin, LC Chen, KY Huang… - 2020 - cdn.amegroups.cn
Background: Autologous chimeric antigen receptor (CAR) T cell therapy is a promising
therapeutic strategy for treating hematologic malignancies. A spectrum of serious …
therapeutic strategy for treating hematologic malignancies. A spectrum of serious …
Pre-clinical assessment of chimeric antigen receptor t cell therapy targeting CD19+ B cell malignancy
SI Hu, MC Ko, YH Dai, HA Lin… - Annals of …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Autologous chimeric antigen receptor (CAR) T cell therapy is a promising
therapeutic strategy for treating hematologic malignancies. A spectrum of serious …
therapeutic strategy for treating hematologic malignancies. A spectrum of serious …
Pre-clinical assessment of chimeric antigen receptor t cell therapy targeting CD19+ B cell malignancy.
SI Hu, MC Ko, YH Dai, HA Lin, LC Chen… - Annals of …, 2020 - europepmc.org
Background Autologous chimeric antigen receptor (CAR) T cell therapy is a promising
therapeutic strategy for treating hematologic malignancies. A spectrum of serious …
therapeutic strategy for treating hematologic malignancies. A spectrum of serious …
[PDF][PDF] Pre-clinical assessment of chimeric antigen receptor t cell therapy targeting CD19+ B cell malignancy
SI Hu, MC Ko, YH Dai, HA Lin, LC Chen, KY Huang… - 2020 - pdfs.semanticscholar.org
Background: Autologous chimeric antigen receptor (CAR) T cell therapy is a promising
therapeutic strategy for treating hematologic malignancies. A spectrum of serious …
therapeutic strategy for treating hematologic malignancies. A spectrum of serious …
[PDF][PDF] Pre-clinical assessment of chimeric antigen receptor t cell therapy targeting CD19+ B cell malignancy
SI Hu, MC Ko, YH Dai, HA Lin, LC Chen, KY Huang… - 2020 - academia.edu
Background: Autologous chimeric antigen receptor (CAR) T cell therapy is a promising
therapeutic strategy for treating hematologic malignancies. A spectrum of serious …
therapeutic strategy for treating hematologic malignancies. A spectrum of serious …
Pre-clinical assessment of chimeric antigen receptor t cell therapy targeting CD19+ B cell malignancy.
SI Hu, MC Ko, YH Dai, HA Lin, LC Chen… - Annals of …, 2020 - europepmc.org
Background Autologous chimeric antigen receptor (CAR) T cell therapy is a promising
therapeutic strategy for treating hematologic malignancies. A spectrum of serious …
therapeutic strategy for treating hematologic malignancies. A spectrum of serious …
[引用][C] Pre-clinical assessment of chimeric antigen receptor t cell therapy targeting CD19+ B cell malignancy
SI Hu, MC Ko, YH Dai, HA Lin, LC Chen… - Annals of …, 2020 - atm.amegroups.org
Pre-clinical assessment of chimeric antigen receptor t cell therapy targeting CD19+ B cell
malignancy - Hu - Annals of Translational Medicine Have a website account?Log In orRegister …
malignancy - Hu - Annals of Translational Medicine Have a website account?Log In orRegister …